Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,073

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

Ebers, George C·1998·The Lancet
DOI 10.1016/s0140-6736(98)03334-0
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(98)03334-0

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 33

  1. Weinshenker, 1989, The natural history of multiple sclerosis: a geographically based study—I: clinical course and disability, Brain, 112, 133, 10.1093/brain/112.1.133 · DOI · Paper page
  2. Weinshenker, 1989, The natural history of multiple sclerosis: a geographically based study—2, predictive value of the early clinical course, Brain, 112, 1419, 10.1093/brain/112.6.1419 · DOI · Paper page
  3. Weinshenker, 1991, The natural history of multiple sclerosis: a geographically based study—4, applications to planning and interpretation of clinical therapeutic trials, Brain, 114, 1057, 10.1093/brain/114.2.1057 · DOI · Paper page
  4. Runmarker, 1993, Prognostic factors in a multiple sclerosis incidence cohort with 25 years of follow-up, Brain, 116, 117, 10.1093/brain/116.1.117 · DOI · Paper page
  5. Weinshenker, 1995, The natural history of multiple sclerosis, Neurol Clin, 13, 119, 10.1016/S0733-8619(18)30064-1 · DOI · Paper page
  6. Young, 1981, Nuclear magnetic resonance imaging of the brain in multiple sclerosis, Lancet, ii, 1063, 10.1016/S0140-6736(81)91273-3 · DOI · Paper page
  7. Paty, 1993, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis-II: MRI analysis results of a multicentre, randomised, double-blind, placebo-controlled trial, Neurology, 43, 662, 10.1212/WNL.43.4.662 · DOI · Paper page
  8. 1995, Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial, Neurology, 45, 1277, 10.1212/WNL.45.7.1277 · DOI · Paper page
  9. Miller, 1988, Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis, Brain, 111, 927, 10.1093/brain/111.4.927 · DOI · Paper page
  10. Ebers, 1994, Treatment of multiple sclerosis, Lancet, 343, 275, 10.1016/S0140-6736(94)91119-3 · DOI
  11. 1993, Interferon beta-1b is effective in relapsing-remitting multiple sclerosis—I: clinical results of a multicentre, randomized, double-blind, placebo-controlled trial, Neurology, 43, 655, 10.1212/WNL.43.4.655 · DOI · Paper page
  12. Jacobs, 1996, Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG), Ann Neurol, 39, 285, 10.1002/ana.410390304 · DOI · Paper page
  13. Rice, 1998, Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?, Arch Neurol, 10.1001/archneur.55.12.1578 · doi:10.1001/archneur.55.12.1578
  14. Thompson, 1996, New treatments for multiple sclerosis: a clinical perspective, Curr Opin Neural, 9, 187, 10.1097/00019052-199606000-00006 · doi:10.1097/00019052-199606000-00006
  15. Jacobs, 1994, A brief history of the use of interferons as treatment of multiple sclerosis, Arch Neurol, 51, 1245, 10.1001/archneur.1994.00540240089022 · DOI
  16. Simon, 1998, Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis, Ann Neurol, 43, 79, 10.1002/ana.410430114 · DOI · Paper page
  17. Pozzilli, 1996, Magnetic resonance imaging changes with recombinant human interferon-β-1a: a short-term study in relapsing-remitting multiple sclerosis, J Neurol Neurosurg Psychiatry, 61, 251, 10.1136/jnnp.61.3.251 · DOI
  18. Johnson, 1990, Recombinant human beta interferon treatment of relapsing-remitting multiple sclerosis: pilot study results, Neurology, 40, 261
  19. Munafo, 1998, Bioavailability of recombinant human interferon-β-1a after intramuscular and subcutaneous administration, Eur J Neural, 5, 187, 10.1046/j.1468-1331.1998.520187.x · doi:10.1046/j.1468-1331.1998.520187.x
  20. Poser, 1983, New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, 13, 227, 10.1002/ana.410130302 · DOI · Paper page
  21. Sandberg-Wollheim, 1995, Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis, Mult Scler, 1, S48
  22. Chernajovsky, 1984, Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-β1 gene fused to an SV40 early promoter, DNA, 3, 297, 10.1089/dna.1.1984.3.297 · DOI
  23. Schumacher, 1968, Problems of experimental trials of therapy in MS: report of the panel on evaluation of experimental trials in MS, Ann N Y Acad Sci, 122, 552, 10.1111/j.1749-6632.1965.tb20235.x · DOI · Paper page
  24. Hauser, 1983, Intensive immunosuppression in progressive multiple sclerosis; a randomised, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH, N Engl J Med, 308, 173, 10.1056/NEJM198301273080401 · DOI · Paper page
  25. Barnes, 1997, Randomised trial of oral and intravenous methylpredisolone in acute relapses of multiple sclerosis, Lancet, 349, 902, 10.1016/S0140-6736(96)06453-7 · DOI · Paper page
  26. Lui, 1998, Summary measure statistic for assessing outcome of treatment trials in relapsing and remitting multiple sclerosis, J Neurol Neurosurg Psychiatry, 64, 726, 10.1136/jnnp.64.6.726 · DOI
  27. Johnson, 1995, Copolymer 1 reduces exacerbation rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicentre, double-blind, placebo-controlled trial, Neurology, 45, 1268, 10.1212/WNL.45.7.1268 · DOI · Paper page
  28. Ebers, 1998, The pathogenesis of MS, Eur J Neurol, 5, S7
  29. Goodkin, 1992, Inter- and intrarater scoring agreement using grades 1·0 to 3·5 of the Kurtzke Expanded Disability Status Scale (EDSS): Multiple Sclerosis Collaborative Research Group, Neurology, 42, 859, 10.1212/WNL.42.4.859 · DOI · Paper page
  30. Noseworthy, 1989, A referendum on clinical trial research in multiple sclerosis: the opinion of the participants at the Jekyll Island Workshop, Neurology, 39, 977, 10.1212/WNL.39.7.977 · doi:10.1212/wnl.39.7.977
  31. Fazekas, 1997, Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis, Lancet, 349, 589, 10.1016/S0140-6736(96)09377-4 · DOI · Paper page
  32. Khan, 1998, Serum interferon-beta-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients, Neurology, 51, 738, 10.1212/WNL.51.3.738 · doi:10.1212/wnl.51.3.738
  33. 1996, Neutralising antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first 3 years, Neurology, 47, 889, 10.1212/WNL.47.4.889 · DOI · Paper page

Cited by

See all 2,073

Metadata

Authors
Ebers, G. C.
Venue
The Lancet
Publisher
Elsevier BV
Published
1998-11
Volume
352
Issue
9139
Pages
1498-1504
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(98)03334-0
OpenAlex
W2169098250
Cited by
2,073
References
2
FWCI
51.15
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. https://app.cochat.ai/papers/10.1016/s0140-6736(98)03334-0
The paper
Ebers, G. C. (1998). Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. The Lancet. https://doi.org/10.1016/s0140-6736(98)03334-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.